Data / Drug companies / Kanchan Healthcare Inc
Kanchan Healthcare Inc: 22 products in the FDA NDC directory, labeler code 85742
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Kanchan Healthcare Inc (labeler code 85742) lists 22 products in the FDA National Drug Code Directory, covering 11 finished drugs by generic name. By type: 22 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 19, 2026.
The request: Watch Kanchan Healthcare Inc (FDA labeler code 85742): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 85742
- Products in commercial distribution
- 22
- Packages
- 32
- Finished drugs by generic name
- 11
- Prescription products
- 22
- Over the counter products
- 0
- Controlled substance products
- Schedule V 5
- Flagged as original packager
- 21 of 21 products that carry the flag
- Started marketing in the last 12 months
- 4
- Earliest marketing start
- December 15, 2006
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 20 | 90.9% |
| Authorized generics (NDA) | 1 | 4.5% |
| New drug applications (NDA) | 1 | 4.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 22 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Lacosamide | 5 | 57 |
| Tizanidine hydrochloride | 3 | 25 |
| Varenicline tartrate | 3 | 23 |
| Erythromycin ethylsuccinate | 2 | 8 |
| Ethambutol hydrochloride | 2 | 7 |
| Metronidazole | 2 | 68 |
| Dexamethasone | 1 | 45 |
| Oxcarbazepine | 1 | 46 |
| Nystatin | 1 | 40 |
| Regadenoson | 1 | 14 |
| Ramelteon | 1 | 29 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 11 | 50% |
| Capsule | 3 | 13.6% |
| For suspension | 2 | 9.1% |
| Suspension | 2 | 9.1% |
| Elixir | 1 | 4.5% |
| Kit | 1 | 4.5% |
| Solution | 1 | 4.5% |
| Injection, solution | 1 | 4.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Metronidazole | 85742-025 | Tablet, film coated | Generic drugs (ANDA) | June 19, 2026 |
| Metronidazole | 85742-024 | Tablet, film coated | Generic drugs (ANDA) | June 19, 2026 |
| Ramelteon | 85742-023 | Tablet, film coated | Generic drugs (ANDA) | April 21, 2026 |
| Dexamethasone | 85742-004 | Elixir | Generic drugs (ANDA) | November 14, 2025 |
| Lacosamide | 85742-011 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2025 |
| Lacosamide | 85742-010 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2025 |
| Lacosamide | 85742-009 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2025 |
| Lacosamide | 85742-008 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2025 |
| Oxcarbazepine | 85742-007 | Suspension | Generic drugs (ANDA) | May 1, 2025 |
| Regadenoson | 85742-012 | Injection, solution | Generic drugs (ANDA) | August 22, 2024 |
| Varenicline tartrate | 85742-017 | Kit | Generic drugs (ANDA) | October 1, 2023 |
| Varenicline tartrate | 85742-016 | Tablet, film coated | Generic drugs (ANDA) | October 1, 2023 |
| Varenicline tartrate | 85742-015 | Tablet, film coated | Generic drugs (ANDA) | October 1, 2023 |
| Lacosamide | 85742-014 | Solution | Generic drugs (ANDA) | February 6, 2023 |
| Erythromycin ethylsuccinate | 85742-030 | For suspension | Generic drugs (ANDA) | November 21, 2022 |
| Erythromycin ethylsuccinate | 85742-029 | For suspension | Generic drugs (ANDA) | November 21, 2022 |
| Nystatin | 85742-013 | Suspension | Generic drugs (ANDA) | August 14, 2020 |
| Tizanidine hydrochloride | 85742-033 | Capsule | Generic drugs (ANDA) | December 29, 2017 |
| Tizanidine hydrochloride | 85742-032 | Capsule | Generic drugs (ANDA) | December 29, 2017 |
| Tizanidine hydrochloride | 85742-031 | Capsule | Generic drugs (ANDA) | December 29, 2017 |
| Ethambutol Hydrochloride | 85742-006 | Tablet, film coated | New drug applications (NDA) | December 15, 2006 |
| Ethambutol Hydrochloride | 85742-005 | Tablet, film coated | Authorized generics (NDA) | December 15, 2006 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.